Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hansoh Pharmaceutical Group Co EV-to-EBITDA?
Hansoh Pharmaceutical Group CoHNSPF 87 EV-to-EBITDA is 22.80 as of Aug. 13, 2026, which is 5% above its 10-year median of 21.75. GuruFocus rates HNSPF with a GF Score™ of 87/100 and a GF Value™ of $3.70 (Modestly Overvalued). Among 734 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks worse than 71.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hansoh Pharmaceutical Group Co's enterprise value is $22,246 Mil.
Hansoh Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $976 Mil. Therefore, Hansoh Pharmaceutical Group Co's EV-to-EBITDA for today is 22.80.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's EV-to-EBITDA or its related term are showing as below:
HNSPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.02 Med: 21.75 Max: 63.53
Current: 22.88
During the past 10 years, the highest EV-to-EBITDA of Hansoh Pharmaceutical Group Co was 63.53. The lowest was 10.02. And the median was 21.75.
HNSPF's EV-to-EBITDA is ranked worse than 71.12% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.355
vs HNSPF: 22.88
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hansoh Pharmaceutical Group Co's PE Ratio (TTM) for today is calculated as:
Hansoh Pharmaceutical Group Co's share price for today is $4.11.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.131.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's EV-to-EBITDA falls into.
Hansoh Pharmaceutical Group Co's current Enterprise Value is $22,246 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $976 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co (HNSPF) has a EV-to-EBITDA of 22.80 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hansoh Pharmaceutical Group Co. This is near median its historical median of 21.75. Over the past decade, Hansoh Pharmaceutical Group Co's EV-to-EBITDA has ranged from 10.02 to 63.53. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #522 out of 734 companies in the Drug Manufacturers industry, placing it in the top 71.1%.
Is Hansoh Pharmaceutical Group Co's EV-to-EBITDA too high?
Hansoh Pharmaceutical Group Co's current EV-to-EBITDA of 22.80 is near median its 10-year median of 21.75. Over the past 10 years, this metric has ranged from a low of 10.02 to a high of 63.53. The Drug Manufacturers industry median EV-to-EBITDA is 13.36. Hansoh Pharmaceutical Group Co's value of 22.80 is 70.7% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #522 out of 734 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #522 out of 734 companies for EV-to-EBITDA. This places Hansoh Pharmaceutical Group Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.36. Hansoh Pharmaceutical Group Co's value of 22.80 is 70.7% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own EV-to-EBITDA has ranged from 10.02 to 63.53 over the past decade. While the company's 10-year median is 21.75 vs. the industry median of 13.36, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.36, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current EV-to-EBITDA of 22.80 is 70.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hansoh Pharmaceutical Group Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current EV-to-EBITDA is 22.80, which is near median its own 10-year median of 21.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.70, compared to a current price of $4.11 — trading 11.1% above its estimated fair value. The current EV-to-EBITDA is 22.80, which is near median its 10-year median of 21.75 and 70.7% above the Drug Manufacturers industry median of 13.36. Hansoh Pharmaceutical Group Co's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current EV-to-EBITDA is 22.80 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $4.11 is trading 11.1% above its estimated GF Value™ of $3.70.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
EV-to-EBITDA: 22.80 (near median its 10-year median of 21.75)
GF Value™: $3.70 vs. price of $4.11 (11.1% above fair value)
Industry Position: 70.7% above the Drug Manufacturers median (#522 of 734)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
87GF Score
Get the complete analysis for HNSPF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
